Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies.
2017-12-08 08:16來源：原版作者：Weissenstein U
Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation with the aim to improve CTC detection with low target antigen densities.
Blood samples of healthy donors spiked with breast cancer cell line HCC1937 were used to determine accuracy and precision of the method. 10 healthy subjects were examined to evaluate specificity. CTC counts in 59 patients with MBC were measured to evaluate the prognostic value on overall survival.
Regression analysis of numbers of recovered vs. spiked HCC1937 cells yielded a coefficient of determination of R(2)?=?0.957. The average percentage of cell recovery was 84%. The average within-run coefficient of variation for spiking of 185, 85 and 30 cells was 14%. For spiking of 10 cells the within-run CV was 30%. No CTCs were detected in blood of 10 healthy subjects examined. A standard threshold of 5 CTC/7.5?ml blood as a cut-off point between risk groups led to a highly significant prognostic marker (p?0.001). To assess the prognostic value of medium CTC levels we additionally considered a low (CTC-L: 0 CTC), a medium (CTC-M: 1-4 CTC) and a high risk group (CTC-H: ≥5 CTC). The effect of this CTC-LMH marker on overall survival was significant as well (p?0.001). A log-ratio test performed to compare the model with 3 vs. the model with 2 risk groups rejected the model with 2 risk groups (p?=?0.026). For CTC as a count variable, we propose an offset reciprocal transformation 1/(1?+?x) for overall survival prediction (p?0.001).
We show that our CTC detection method is feasible and leads to accurate and reliable results. Our data suggest that a refined differentiation between patients with different CTC levels is reasonable.
(BMC Cancer. 2012 May 30;12:206.)
- > 《醫學拾萃》2019年11月刊：靜脈血和末梢血在臨床檢測項目中的差別應用（續）
- > 《醫學拾萃》2019年10月刊：靜脈血和末梢血在臨床檢測項目中的差別應用
- > 《醫學拾萃》2019年9月刊：腎素-血管緊張素-醛固酮系統（RAAS）及其在相關疾病中的調節作用
- > 《醫學拾萃》2019年8月刊：樣本收集和液體活檢對胰腺癌早期診斷的意義
- > 《醫學拾萃》2019年7月刊：全血 RNA 管的應用以及基因表達譜
- > 《醫學拾萃》2019年6月刊：血小板釋放
- > 《醫學拾萃》2019年5月刊：臨檢樣本溶血的原因、鑒定以及對臨檢指標的影響
- > 《醫學拾萃》2019年4月刊：對臨檢樣本分析前誤差的來源和分布的統計
- > 《醫學拾萃》2019年3月刊：巨噬細胞與腫瘤細胞的多重互動及其臨床意義
- > 《醫學拾萃》2019年2月刊：中性粒細胞對腫瘤和循環腫瘤細胞的保護和促進作用